Výsledky vyhledávání - "Mikhail Khmelevskii"

Akademický článek

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

Autor: Dmitry Lioznov, Irina Amosova, Savely A Sheetikov, Ksenia V Zornikova, Yana Serdyuk, Grigory A Efimov, Mikhail Tsyferov, Mikhail Khmelevskii, Andrei Afanasiev, Nadezhda Khomyakova, Dmitry Zubkov, Anton Tikhonov, Tao Zhu, Luis Barreto, Vitalina Dzutseva

Publikováno v: PLoS ONE, Vol 18, Iss 3, p e0278878 (2023)

BackgroundTo determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 1010 viral particles per 0.5 mL dose), we conducted a single-dose, randomised,

Externí odkaz: https://doaj.org/article/08e8fcb72ba646b8815b34a3a91ff517

Zobrazit plný text záznamu

Plný text ve formátu HTML

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia

Autor: Dmitry Lioznov, Irina Amosova, Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, Mikhail Tsyferov, Mikhail Khmelevskii, Andrei Afanasiev, Nadezhda Khomyakova, Dmitry Zubkov, Anton Tikhonov, Tao Zhu, Luis Barreto, Vitalina Dzutseva

Background To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 1010 viral particles per 0.5 mL dose), we conducted a single-dose, randomised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd04a5ae89b742b9b6b674b5ee71880
https://doi.org/10.1101/2022.03.01.22271507

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání